



UNITED STATES PATENT AND TRADEMARK OFFICE

OCT 27 2010

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Office of Regulatory Policy
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Rm. 6222
Silver Spring, MD 20993-0002

Attention: Beverly Friedman


Dear Ms. Axelrad:

This is in regard to the application for patent term extension for U.S. Patent No. 6,589,508 (the '508 patent) filed December 1, 2006, and forwarded to FDA on March 13, 2007.

The Federal Circuit recently upheld the validity of a patent term extension for a patent claiming an enantiomer in light a previous approval of a racemate having the same chemical formula. In *Ortho-McNeil Pharm., Inc. v. Lupin Pharms., Inc.*, 603 F.3d 1377 (Fed. Cir. 2010), a generic pharmaceutical company was sued for patent infringement under the provisions of 35 U.S.C. § 271(e)(2) and defended against infringement by asserting that the USPTO improperly issued an extension of the term of a patent (U.S. Patent No. 5,053,407) which claimed the human drug product Levaquin® (levofloxacin) and hence the patent (extension) was invalid and could not be infringed. The basis for the challenge to the propriety of the patent term extension was that the approval of Levaquin® did not represent the first permitted commercial marketing or use of the drug product as required by 35 U.S.C. § 156(a)(5)(A) because the racemate, Floxin® (ofloxacin), was approved before a single enantiomer of ofloxacin, Levaquin®. The USPTO maintains that a patent which claims an enantiomer, which was subject to regulatory review before FDA before its commercial marketing or use, is eligible for extension even if a racemate having the same chemical formula had been previously approved. That is, the approval of a racemate does not exhaust patent term extension for either an R or S enantiomer of the racemate. In upholding the validity of the patent term extension for Ortho-McNeil's Levaquin®, the court concluded that "the enantiomer [levofloxacin] is a different drug product from the racemate ofloxacin" *Id.* at. 1381.

Here, the '508 patent claims a method of using arformoterol. Arformoterol (formulated as the tartrate salt), the subject of NDA No. 21-912 which was approved by FDA on October 6, 2006, is the active ingredient in the human drug product Brovana®. Formoterol (formulated as the fumerate salt) is a racemate having the same chemical formula as arformoterol and was approved by FDA on February 16, 2001. In accordance with the holding of *Ortho-McNeil Pharm., Inc. v. Lupin Pharms., Inc.*, it is the position of the USPTO that the patent claiming a method of using arformoterol (Brovana®) is eligible for patent term extension since the approval of Brovana® complies with the requirement of section 156(a)(5)(A). Thus, is it requested the FDA make their determination on eligibility for U.S. Patent No. 6,589,508 in accordance with the decision articulated by the Federal Circuit in *Ortho-McNeil Pharm., Inc. v. Lupin Pharms., Inc.*

Inquiries regarding this communication should be directed to the undersigned at (571) 272-7755 (telephone) or (571) 273-7755 (facsimile).



Mary C. Till

Legal Advisor

Office of Patent Legal Administration

Office of the Associate Commissioner

for Patent Examination Policy

cc: Anthony M. Insogna, Esq.
JONES DAY
222 East 41st Street
New York, NY 10017

RE: BROVANA® (arformoterol tartrate)
Docket No.: FDA-2007-E-0226